ClinicalTrials.gg
CompletedNCT01277718Updated May 10, 2017Results posted

A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants

A Phase 1 interventional study of Cobimetinib and Rabeprazole in Healthy Volunteer, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, single-center, open-label, randomized, 3-period, 2-sequence crossover study of cobimetinib in healthy participants to evaluate the effect of the proton-pump inhibitor (PPI) rabeprazole on the relative bioavailability of cobimetinib in healthy participants when administered in the fed or fasted states.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With a range of 18.5 to 29.9 kilograms per meter square (kg/m\^2)
  • In good health, determined by no findings from medical history, 12-lead (ECG), and vital signs
  • Clinical laboratory evaluations within the reference range for the test laboratory
  • Negative test for selected drugs of abuse at Screening (does not include alcohol) and at each Check-in
  • Negative hepatitis panel (including virus surface antigen [HBsAg] and virus antibody [anti-HCV]) and negative (HIV) antibody screens
  • Healthy males and females of nonchildbearing potential who agree to use effective

Exclusion criteria

Exclusion Criteria

  • Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs, except that appendectomy, hernia repair, and/or cholecystectomy will be allowed
  • History or presence of an abnormal
  • History of alcoholism or drug addiction within 1 year prior to Period 1 Check-in
  • Use of any tobacco- or nicotine-containing products within 6 months prior to Period 1 Check-in
  • Participation in any other study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Period 1 Check-in
  • Use of any prescription medications/products within 14 days prior to Period 1 Check-in
  • Use of any over-the-counter, non-prescription preparations within 7 days prior to Period 1 Check-in
  • Use of alcohol-, grapefruit-, or caffeine-containing foods or beverages within 72 hours prior to Period 1 Check-in
  • Poor peripheral venous access
  • Any acute or chronic condition that would limit the participant's ability to complete and/or participate in this clinical study
  • Female participant is pregnant, lactating, or breastfeeding
  • Use of PPIs or histamine H2 receptor antagonists within 1 month prior to Period 1 Check-in
  • Known hypersensitivity to rabeprazole or any of its components or to derived products of benzimidazoles
  • Predisposing factors to retinal vein occlusion (RVO)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A first, then Treatment B, followed by Treatment C

    Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.

    Drug: Cobimetinib · Drug: Rabeprazole

  • Experimental
    Treatment A first, then Treatment C, followed by Treatment B

    Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.

    Drug: Cobimetinib · Drug: Rabeprazole

Interventions

  • One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.

    Also known as: GDC-0973, XL518

  • Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

    Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

  2. Maximum Observed Concentration of Cobimetinib

    Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose

07

Results

Posted Jul 7, 2016

Participant flow

Period 1 - First Intervention
Participant flow — Period 1 - First Intervention
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment B
Started1010
Completed1010
Not completed00
Washout Period of 13 Days
Participant flow — Washout Period of 13 Days
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment B
Started1010
Completed1010
Not completed00
Period 2 - Second Intervention
Participant flow — Period 2 - Second Intervention
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment B
Started1010
Completed107
Not completed03
Withdrew: Protocol violation01
Withdrew: Physician decision02
Washout Period of 13 Days
Participant flow — Washout Period of 13 Days
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment B
Started107
Completed107
Not completed00
Period 3 - Third Intervention
Participant flow — Period 3 - Third Intervention
MilestoneTreatment A First, Then Treatment B, Followed by Treatment CTreatment A First, Then Treatment C, Followed by Treatment B
Started107
Completed107
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

Time frame:
Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib
nanograms*hours/milliliter (ng*hr/mL)Cobimetinib [Fasted]Cobimetinib [Fasted] + RabeprazoleCobimetinib [Fed] + Rabeprazole
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib778 ± 32.8864 ± 39.1846 ± 48.2
Statistical analysis
  • Cobimetinib [Fasted] vs Cobimetinib [Fasted] + Rabeprazole · Ratio of least squares (ls) means (in %): 111 · 90% CI 98.02 to 124.99LS mean was calculated from Analysis of variance (ANOVA). Data for AUCinf were natural log-transformed prior to analysis. Ratio of AUCinf LS means for log-transformed parameter (expressed as a percent).
  • Cobimetinib [Fasted] + Rabeprazole vs Cobimetinib [Fed] + Rabeprazole · Ratio of ls means (in %): 96.2 · 90% CI 85.06 to 108.77LS mean was calculated from ANOVA. Data for AUCinf were natural log-transformed prior to analysis. Ratio of AUCinf LS means for log-transformed parameter (expressed as a percent).
  • Cobimetinib [Fasted] vs Cobimetinib [Fed] + Rabeprazole · Ratio of ls means (in %): 106 · 90% CI 94.53 to 119.91LS mean was calculated from ANOVA. Data for AUCinf were natural log-transformed prior to analysis. Ratio of AUCinf LS means for log-transformed parameter (expressed as a percent).
PrimaryMaximum Observed Concentration of Cobimetinib
Time frame:
Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Observed Concentration of Cobimetinib
nanograms per milliliter (ng/mL)Cobimetinib [Fasted]Cobimetinib [Fasted] + RabeprazoleCobimetinib [Fed] + Rabeprazole
Maximum Observed Concentration of Cobimetinib17.0 ± 35.317.2 ± 36.014.8 ± 51.2
Statistical analysis
  • Cobimetinib [Fasted] vs Cobimetinib [Fasted] + Rabeprazole · Ratio of ls means (in %): 100 · 90% CI 85.09 to 118.03LS mean was calculated from ANOVA. Data for Cmax were natural log-transformed prior to analysis. Ratio of Cmax LS means for log-transformed parameter (expressed as a percent).
  • Cobimetinib [Fasted] + Rabeprazole vs Cobimetinib [Fed] + Rabeprazole · Ratio of ls means (in %): 85.7 · 90% CI 72.51 to 101.33LS mean was calculated from ANOVA. Data for Cmax were natural log-transformed prior to analysis. Ratio of Cmax LS means for log-transformed parameter (expressed as a percent).
  • Cobimetinib [Fasted] vs Cobimetinib [Fed] + Rabeprazole · Ratio of ls means (in %): 85.9 · 90% CI 72.94 to 101.17LS mean was calculated from ANOVA. Data for Cmax were natural log-transformed prior to analysis. Ratio of Cmax LS means for log-transformed parameter (expressed as a percent).

Adverse events

Collected over Adverse events were recorded from start of study treatment in first period to end of last period (up to 36 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cobimetinib [Fasted]—0/20 (0%)8/20 (40%)
Cobimetinib [Fasted] + Rabeprazole—0/17 (0%)10/17 (58.8%)
Cobimetinib [Fed] + Rabeprazole—0/20 (0%)9/20 (45%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventCobimetinib [Fasted]Cobimetinib [Fasted] + RabeprazoleCobimetinib [Fed] + Rabeprazole
NauseaGastrointestinal disorders0/202/172/20
Neck painMusculoskeletal and connective tissue disorders0/202/171/20
HeadacheNervous system disorders2/202/172/20
DizzinessNervous system disorders0/202/172/20
DiarrhoeaGastrointestinal disorders0/200/172/20
VomitingGastrointestinal disorders0/200/172/20
ChillsGeneral disorders0/200/172/20
Gastroenteritis viralInfections and infestations0/201/171/20
Oral herpesInfections and infestations0/201/170/20
Back painMusculoskeletal and connective tissue disorders0/201/170/20

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean31 (22 to 53)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female4
Male16
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2011
First posted
Jan 17, 2011
Start
Jan 2011
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Jul 7, 2016
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01277718
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jan 17, 2011
Start date
Jan 2011
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Jul 7, 2016
Last update
May 10, 2017

Study contacts

Isabelle Rooney, M.D., PhD
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion